Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions
Acute Lymphoblastic LeukemiaStem Cell Transplantation, Hematopoietic
Interventions
DRUG

TBI+CY+VP-16

CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d

DRUG

FA+TBI+CY+VP-16

NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d

Trial Locations (1)

510515

Department of Hematology, Nanfang Hospital, Guangzhou

All Listed Sponsors
collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT01457040 - Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter